Locally advanced and metastatic sarcoma (adult type) including gastrointestinal stromal tumors

Critical Reviews in Oncology/Hematology

Volumn 60, Issue 2, 2006, Pages 112-130

  Bauer, Sebastian ^a   Hartmann, Joerg T ^b  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Chemotherapy; Gastrointestinal stromal tumor; Imatinib mesylate; Localized disease; Metastatic disease; Pathology; Prognosis; Radiation; Soft tissue sarcoma; Surgery; Treatment

Indexed keywords

4 METHYL N [3 (4 METHYL 1 IMIDAZOLYL) 5 (TRIFLUOROMETHYL)PHENYL] 3 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINO]BENZAMIDE; AMG 706; AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; AP 23573; BORTEZOMIB; CANCER VACCINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EVEROLIMUS; GEMCITABINE; IFOSFAMIDE; IMATINIB; IPI 504; MAGE 12; MITOMYCIN; MITOMYCIN C; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; N BENZOYLSTAUROSPORINE; NY ESO 1 ANTIGEN; PACLITAXEL; REBECAMYCIN; RUBITECAN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TETRACYCLINE DERIVATIVE; TRABECTEDIN; TROFOSFAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADVANCED CANCER; ANEMIA; BLEEDING; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER LOCALIZATION; CANCER STAGING; CLINICAL TRIAL; DIARRHEA; DRUG ERUPTION; DYSPNEA; EDEMA; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LEUKOPENIA; LIVER FAILURE; METASTASIS; NAUSEA; NEUTROPENIA; PALLIATIVE THERAPY; PATHOGENESIS; PATHOLOGY; PLEURAL PAIN; PROGNOSIS; REVIEW; SEPSIS; THROMBOCYTOPENIA; VOMITING;

CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; COMBINED MODALITY THERAPY; GASTROINTESTINAL STROMAL TUMORS; HUMANS; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY, ADJUVANT; SARCOMA; TREATMENT OUTCOME;

EID: 33751012431     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2006.06.010     Document Type: Review

References (138)

1. Fletcher J.A. Molecular biology and cytogenetics of soft tissue sarcomas: relevance for targeted therapies. Cancer Treat Res 120 (2004) 99-116
2. Fletcher J.A. Cytogenetics and molecular biology of soft tissue tumors. Monogr Pathol 38 (1996) 37-64
3. Enzinger F.M., and Weiss S.W. Soft tissue tumors. 4th ed. (2001), Mosby Company, St. Louis
4. Mazeron J.J., and Suit H.D. Lymph nodes as sites of metastases from sarcomas of soft tissue. Cancer 60 (1987) 1800-1808
5. Kirkpatrick C.J., Alves A., Kohler H., et al. Biomaterial-induced sarcoma: a novel model to study preneoplastic change. Am J Pathol 156 (2000) 1455-1467
6. Hogendoorn P.C., Collin F., Daugaard S., et al. Changing concepts in the pathological basis of soft tissue and bone sarcoma treatment. Eur J Cancer 40 (2004) 1644-1654
7. Guillou L., Coindre J.M., Bonichon F., et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 15 (1997) 350-362
8. Fletcher C.D.M., Unni K.K., and Mertens F. Pathology and genetics of tumors of soft tissue and bone (2002), IARC Press, Lyon
9. Grobmyer S.R., and Brennan M.F. Predictive variables detailing the recurrence rate of soft tissue sarcomas. Curr Opin Oncol 15 (2003) 319-326
10. Lawrence Jr. W., Gehan E.A., Hays D.M., Beltangady M., and Maurer H.M. Prognostic significance of staging factors of the UICC staging system in childhood rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS-II). J Clin Oncol 5 (1987) 46-54
11. Lawrence Jr. W., Donegan W.L., Natarajan N., Mettlin C., Beart R., and Winchester D. Adult soft tissue sarcomas. A pattern of care survey of the American College of Surgeons. Ann Surg 205 (1987) 349-359
12. Eilber F.C., Rosen G., Nelson S.D., et al. High-grade extremity soft tissue sarcomas: factors predictive of local recurrence and its effect on morbidity and mortality. Ann Surg 237 (2003) 218-226
13. Pisters P.W., Leung D.H., Woodruff J., Shi W., and Brennan M.F. Analysis of prognostic factors in 1041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 14 (1996) 1679-1689
14. Billingsley K.G., Lewis J.J., Leung D.H., Casper E.S., Woodruff J.M., and Brennan M.F. Multifactorial analysis of the survival of patients with distant metastasis arising from primary extremity sarcoma. Cancer 85 (1999) 389-395
15. Lewis J.J., Leung D., Woodruff J.M., and Brennan M.F. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann Surg 228 (1998) 355-365
16. Stojadinovic A., Yeh A., and Brennan M.F. Completely resected recurrent soft tissue sarcoma: primary anatomic site governs outcomes. J Am Coll Surg 194 (2002) 436-447
17. Dematteo R.P., Lewis J.J., Leung D., Mudan S.S., Woodruff J.M., and Brennan M.F. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231 (2000) 51-58
18. Miettinen M., and Lasota J. Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 438 (2001) 1-12
19. Ng E.H., Pollock R.E., and Romsdahl M.M. Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas. Cancer 69 (1992) 1334-1341
20. Mudan S.S., Conlon K.C., Woodruff J.M., Lewis J.J., and Brennan M.F. Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection. Cancer 88 (2000) 66-74
21. Emory T.S., Sobin L.H., Lukes L., Lee D.H., and O'Leary T.J. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 23 (1999) 82-87
22. Taniguchi M., Nishida T., Hirota S., et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 59 (1999) 4297-4300
23. Van Glabbeke M., van Oosterom A.T., Oosterhuis J.W., et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2185 patients treated with anthracycline-containing first-line regimens-a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 17 (1999) 150-157
24. Blay J.Y., Van Glabbeke M., Verweij J., et al. Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer 39 (2003) 64-69
25. Putnam Jr. J.B., and Roth J.A. Surgical treatment for pulmonary metastases from sarcoma. Hematol Oncol Clin North Am 9 (1995) 869-887
26. Wiklund T., Saeter G., Strander H., Alvegard T., and Blomqvist C. The outcome of advanced soft tissue sarcoma patients with complete tumour regression after either chemotherapy alone or chemotherapy plus surgery. The Scandinavian Sarcoma Group experience. Eur J Cancer 33 (1997) 357-361
27. Borden E.C., Baker L.H., Bell R.S., et al. Soft tissue sarcomas of adults: state of the translational science. Clin Cancer Res 9 (2003) 1941-1956
28. Antonescu C.R., Leung D.H., Dudas M., et al. Alterations of cell cycle regulators in localized synovial sarcoma: a multifactorial study with prognostic implications. Am J Pathol 156 (2000) 977-983
29. Antonescu C.R., Tschernyavsky S.J., Decuseara R., et al. Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. Clin Cancer Res 7 (2001) 3977-3987
30. Abudu A., Mangham D.C., Reynolds G.M., et al. Overexpression of p53 protein in primary Ewing's sarcoma of bone: relationship to tumour stage, response and prognosis. Br J Cancer 79 (1999) 1185-1189
31. Kawai A., Woodruff J., Healey J.H., Brennan M.F., Antonescu C.R., and Ladanyi M. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med 338 (1998) 153-160
32. Ladanyi M., Antonescu C.R., Leung D.H., et al. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res 62 (2002) 135-140
33. Guillou L., Benhattar J., Bonichon F., et al. Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J Clin Oncol 22 (2004) 4040-4050
34. Zoubek A., Dockhorn-Dworniczak B., Delattre O., et al. Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients?. J Clin Oncol 14 (1996) 1245-1251
35. de Alava E., Kawai A., Healey J.H., et al. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol 16 (1998) 1248-1255
36. Ginsberg J.P., de Alava E., Ladanyi M., et al. EWS-FLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in Ewing's sarcoma. J Clin Oncol 17 (1999) 1809-1814
37. Kelly K.M., Womer R.B., Sorensen P.H., Xiong Q.B., and Barr F.G. Common and variant gene fusions predict distinct clinical phenotypes in rhabdomyosarcoma. J Clin Oncol 15 (1997) 1831-1836
38. Sorensen P.H., Lynch J.C., Qualman S.J., et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J Clin Oncol 20 (2002) 2672-2679
39. Oliveira A.M., and Fletcher C.D. Molecular prognostication for soft tissue sarcomas: are we ready yet?. J Clin Oncol 22 (2004) 4031-4034
40. Oliveira A.M., and Fletcher J.A. CHIPing soft tissue tumors: will the paradigms be changed?. Adv Anat Pathol 10 (2003) 1-7
41. Heinrich M.C., Corless C.L., Demetri G.D., et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21 (2003) 4342-4349
42. Phan A., and Patel S. Advances in neoadjuvant chemotherapy in soft tissue sarcomas. Curr Treat Options Oncol 4 (2003) 433-439
43. Clarkson P., and Ferguson P.C. Management of soft tissue sarcomas of the extremities. Expert Rev Anticancer Ther 4 (2004) 237-246
44. Clarkson P., and Ferguson P.C. Primary multidisciplinary management of extremity soft tissue sarcomas. Curr Treat Opt Oncol 5 (2004) 451-462
45. Strander H., Turesson I., and Cavallin-Stahl E. A systematic overview of radiation therapy effects in soft tissue sarcomas. Acta Oncol 42 (2003) 516-531
46. Frustaci S., Gherlinzoni F., De Paoli A., et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol 19 (2001) 1238-1247
47. Tepper J.E., and Suit H.D. Radiation therapy alone for sarcoma of soft tissue. Cancer 56 (1985) 475-479
48. Suit H., and Spiro I. Radiation as a therapeutic modality in sarcomas of the soft tissue. Hematol Oncol Clin North Am 9 (1995) 733-746
49. Meric F., Milas M., Hunt K.K., et al. Impact of neoadjuvant chemotherapy on postoperative morbidity in soft tissue sarcomas. J Clin Oncol 18 (2000) 3378-3383
50. Gortzak E., Azzarelli A., Buesa J., et al. A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur J Cancer 37 (2001) 1096-1103
51. Grobmyer S.R., Maki R., Demetri G.D., Riedel E., Brennan M.F., and Singer S. Neo-adjuvant chemotherapy for primary high grade extremity soft tissue sarcoma: a matched case control study [abstract]. Proc Am Soc Clin Oncol 22 (2003) 815
52. Azzarelli A., Quagliuolo V., Casali P., Fissi S., Montalto F., and Santoro A. Preoperative doxorubicin plus ifosfamide in primary soft-tissue sarcomas of the extremities. Cancer Chemother Pharmacol 31 Suppl 2 (1993) S210-S212
53. O'Sullivan B., Davis A.M., Turcotte R., et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet 359 (2002) 2235-2241
54. Spiro I.J., Suit H., Gebhardt M., et al. Neoadjuvant chemotherapy and radiotherapy for large soft tissue sarcomas [abstract]. Proc Am Soc Clin Oncol (1996) 15
55. DeLaney T.F., Spiro I.J., Suit H.D., et al. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int J Radiat Oncol Biol Phys 56 (2003) 1117-1127
56. Kraybill W.G., Harris J.H., Spiro I., et al. Radiation Therapy Oncology Group (RTOG) 9514: a phase II study of neoadjuvant chemotherapy (CT) and radiation therapy (RT) in the management of high risk (HR), high grade, soft tissue sarcomas (STS) of the extremities and body wall. Proc Am Soc Clin Oncol 815 (2003) a3276
57. Eilber F.C., Rosen G., Eckardt J., et al. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol 19 (2001) 3203-3209
58. Schlemmer M., Wendtner C.M., Lindner L., Abdel-Rahman S., Hiddemann W., and Issels R.D. Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term local-failure-free survival for patients with high-risk soft tissue sarcomas. Proc Am Soc Clin Oncol 817 (2003) a3285
59. Wendtner C.M., Abdel-Rahman S., Krych M., et al. Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas. J Clin Oncol 20 (2002) 3156-3164
60. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-Analysis colloboration. Lancet 1997; 350:1647-1654.
61. Frustaci S., De Paoli A., Bidoli E., et al. Ifosfamide in the adjuvant therapy of soft tissue sarcomas. Oncology 65 (2003) 80-84
62. Clark M.A., and Thomas J.M. Amputation for soft-tissue sarcoma. Lancet Oncol 4 (2003) 335-342
63. Sugarbaker P.H., Barofsky I., Rosenberg S.A., and Gianola F.J. Quality of life assessment of patients in extremity sarcoma clinical trials. Surgery 91 (1982) 17-23
64. Yasko A.W., Reece G.P., Gillis T.A., and Pollock R.E. Limb-salvage strategies to optimize quality of life: the M.D. Anderson Cancer Center experience. CA Cancer J Clin 47 (1997) 226-238
65. Pisters P.W., Patel S.R., Varma D.G., et al. Preoperative chemotherapy for stage IIIB extremity soft tissue sarcoma: long-term results from a single institution. J Clin Oncol 15 (1997) 3481-3487
66. Edmonson J.H., Petersen I.A., Shives T.C., et al. Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor. Cancer 94 (2002) 786-792
67. Gaynor J.J., Tan C.C., Casper E.S., et al. Refinement of clinicopathologic staging for localized soft tissue sarcoma of the extremity: a study of 423 adults. J Clin Oncol 10 (1992) 1317-1329
68. Lienard D., Ewalenko P., Delmotte J.J., Renard N., and Lejeune F.J. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10 (1992) 52-60
69. Eggermont A.M., Schraffordt K.H., Klausner J.M., et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 224 (1996) 756-764
70. Eggermont A.M., and ten Hagen T.L. Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: credits, debits, and future perspectives. Curr Oncol Rep 3 (2001) 359-367
71. Wieberdink J., Benckhuysen C., Braat R.P., van Slooten E.A., and Olthuis G.A. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 18 (1982) 905-910
72. Hohenberger P., Latz E., Kettelhack C., Rezaei A.H., Schumann R., and Schlag P.M. Pentoxifyllin attenuates the systemic inflammatory response induced during isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan. Ann Surg Oncol 10 (2003) 562-568
73. Olieman A.F., Pras E., van Ginkel R.J., Molenaar W.M., Schraffordt K.H., and Hoekstra H.J. Feasibility and efficacy of external beam radiotherapy after hyperthermic isolated limb perfusion with TNF-alpha and melphalan for limb-saving treatment in locally advanced extremity soft-tissue sarcoma. Int J Radiat Oncol Biol Phys 40 (1998) 807-814
74. Reichardt P. High-dose chemotherapy in adult soft tissue sarcoma. Crit Rev Oncol Hematol 41 (2002) 157-167
75. Nicolella D., Maione P., and Gridelli C. Targeted therapies: focus on a new strategy for gastrointestinal tumors. Crit Rev Oncol Hematol 47 (2003) 261-271
76. Van Glabbeke M., Verweij J., Judson I., and Nielsen O.S. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 38 (2002) 543-549
77. Hensley M.L., Maki R., Venkatraman E., et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 20 (2002) 2824-2831
78. Spath-Schwalbe E., Genvresse I., Koschuth A., Dietzmann A., Grunewald R., and Possinger K. Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. Anticancer Drugs 11 (2000) 325-329
79. Svancarova L., Blay J.Y., Judson I.R., et al. Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J Cancer 38 (2002) 556-559
80. Okuno S., Edmonson J., Mahoney M., Buckner J.C., Frytak S., and Galanis E. Phase II trial of gemcitabine in advanced sarcomas. Cancer 94 (2002) 3225-3229
81. Hartmann J.T., Oechsle K., and Huober J. An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated advanced soft tissue sarcoma [abstract no. P0878]. J Cancer Res Clin Oncol 130 (2004) S192
82. Okuno S., Ryan L.M., Edmonson J.H., Priebat D.A., and Blum R.H. Phase II trial of gemcitabine in patients with advanced sarcomas (E1797): a trial of the Eastern Cooperative Oncology Group. Cancer 97 (2003) 1969-1973
83. Amodio A., Carpano S., Manfredi C., et al. Gemcitabine in advanced stage soft tissue sarcoma: a phase II study. Clin Ter 150 (1999) 17-20
84. Bauer S., Seeber S., and Schutte J. Gemcitabine in the treatment of soft tissue sarcomas. Onkologie 27 (2004) 180-186
85. Look K.Y., Sandler A., Blessing J.A., Lucci III J.A., and Rose P.G. Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study. Gynecol Oncol 92 (2004) 644-647
86. Leu K.M., Ostruszka L.J., Shewach D., et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol 22 (2004) 1706-1712
87. Verweij J., Lee S.M., Ruka W., et al. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the European organization for research and treatment of cancer soft tissue and bone sarcoma group. J Clin Oncol 18 (2000) 2081-2086
88. Fata F., O'Reilly E., Ilson D., et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 86 (1999) 2034-2037
89. Fury M.G., Antonescu C.R., Van Zee K.J., Brennan M.F., and Maki R.G. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J 11 (2005) 241-247
90. Demetri G.D. ET-743: the US experience in sarcomas of soft tissues. Anticancer Drugs 13 Suppl 1 (2002) S7-S9
91. Yovine A., Riofrio M., Blay J.Y., et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 22 (2004) 890-899
92. Garcia-Carbonero R., Supko J.G., Manola J., et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 22 (2004) 1480-1490
93. Le Cesne A., Blay J.Y., Judson I., et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 23 (2005) 576-584
94. Hartmann J.T., and Patel S. Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma. Drugs 65 (2005) 167-178
95. Merimsky O. Targeting metastatic leiomyosarcoma by rapamycin plus gemcitabine: an intriguing clinical observation. Int J Mol Med 14 (2004) 931-935
96. Baker L.H., Demetri G.D., Mendelson D.S., et al. A randomized phase 2 study of the thrombospondin-mimetic peptide ABT-510 in patients with advanced soft tissue sarcoma (STS) [abstract]. Proc Am Soc Clin Oncol 24 (2005)
97. Balcerzak S.P., Benedetti J., Weiss G.R., and Natale R.B. A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas. A Southwest Oncology Group Study. Cancer 76 (1995) 2248-2252
98. Gallup D.G., Blessing J.A., Andersen W., and Morgan M.A. Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol 89 (2003) 48-51
99. Pivot X., Chevreau C., Cupissol D., et al. Phase II trial of paclitaxel-epirubicin in patients with recurrent soft-tissue sarcoma. Am J Clin Oncol 25 (2002) 561-564
100. van Hoesel Q.G., Verweij J., Catimel G., et al. Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. Ann Oncol 5 (1994) 539-542
101. Kostler W.J., Brodowicz T., Attems Y., et al. Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial. Ann Oncol 12 (2001) 1281-1288
102. Patel S.R., Beach J., Papadopoulos N., et al. Results of a 2-arm Phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas. Cancer 97 (2003) 2848-2852
103. Kollmannsberger C., Brugger W., Hartmann J.T., et al. Phase II study of oral trofosfamide as palliative therapy in pretreated patients with metastatic soft-tissue sarcoma. Anticancer Drugs 10 (1999) 453-456
104. Hartmann J.T., Oechsle K., Mayer F., Kanz L., and Bokemeyer C. Phase II trial of trofosfamide in patients with advanced pretreated soft tissue sarcomas. Anticancer Res 23 (2003) 1899-1901
105. Blomqvist C., Wiklund T., Pajunen M., Virolainen M., and Elomaa I. Oral trofosfamide: an active drug in the treatment of soft-tissue sarcoma. Cancer Chemother Pharmacol 36 (1995) 263-265
106. Billingsley K.G., Burt M.E., Jara E., et al. Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival. Ann Surg 229 (1999) 602-610
107. Abdalla E.K., and Pisters P.W. Metastasectomy for limited metastases from soft tissue sarcoma. Curr Treat Opt Oncol 3 (2002) 497-505
108. Lang H., Nussbaum K.T., Kaudel P., Fruhauf N., Flemming P., and Raab R. Hepatic metastases from leiomyosarcoma: a single-center experience with 34 liver resections during a 15-year period. Ann Surg 231 (2000) 500-505
109. Ng E.H., Pollock R.E., Munsell M.F., Atkinson E.N., and Romsdahl M.M. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 215 (1992) 68-77
110. Scaife C.L., Hunt K.K., Patel S.R., et al. Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate?. Am J Surg 186 (2003) 665-669
111. Bauer S., Hartmann J.T., de Wit M., et al. Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer 117 (2005) 316-325
112. Hirota S., Isozaki K., Moriyama Y., et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279 (1998) 577-580
113. Heinrich M.C., Corless C.L., Duensing A., et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299 (2003) 708-710
114. Wardelmann E., Hrychyk A., Merkelbach-Bruse S., et al. Association of platelet-derived growth factor receptor alpha mutations with gastric primary site and epithelioid or mixed cell morphology in gastrointestinal stromal tumors. J Mol Diagn 6 (2004) 197-204
115. Fletcher C.D., Berman J.J., Corless C., et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33 (2002) 459-465
116. Medeiros F., Corless C.L., Duensing A., et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 28 (2004) 889-894
117. Bauer S., Corless C.L., Heinrich M.C., et al. Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT. Cancer Chemother Pharmacol 51 (2003) 261-265
118. Antonescu C.R., Sommer G., Sarran L., et al. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 9 (2003) 3329-3337
119. Cho H., Tsuburaya A., Kobayashi O., Sairenji M., and Motohashi H. A risk estimation with tumor size, serosal invasion and MIB-1 labeling index for gastrointestinal stromal tumor (GIST) of the stomach. Proc Am Soc Clin Oncol 22 (2004) 9025
120. Blanke C.D., Joensuu H., Demetri G., et al. Long-term follow up of advanced gastrointestinal stromal tumor (GIST) patients treated with imatinib mesylate [abstract]. Proc Am Soc Clin Oncol 23 (2004)
121. Pierie J.P., Choudry U., Muzikansky A., Yeap B.Y., Souba W.W., and Ott M.J. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 136 (2001) 383-389
122. Dematteo R.P., Shah A., Fong Y., Jarnagin W.R., Blumgart L.H., and Brennan M.F. Results of hepatic resection for sarcoma metastatic to liver. Ann Surg 234 (2001) 540-547
123. van Oosterom A.T., Judson I.R., Verweij J., et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 38 Suppl 5 (2002) S83-S87
124. Rankin C., Von Mehren B., Blanke C., et al. Dose effect of imatinib (IM) in patients (pts) with metastatic GIST-Phase III Sarcoma Group Study S0033. Proc Am Soc Clin Oncol (2004) 9005
125. Verweij J., Casali P.G., Zalcberg J., et al. Early efficacy comparison of two doses of imatinib for the treatment of advanced gastro-intestinal stromal tumors (GIST): interim results of a randomized phase III trial from the EORTC-STBSG, ISG and AGITG. Proc Am Soc Clin Oncol 22 (2003) 3272
126. Blay J.Y., Berthaud P., Perol D., et al. Continuous vs. intermittent imatinib treatment in advanced GIST after one year: a prespective randomized phase III trial of the French Sarcoma Group [abstract]. Proc Am Soc Clin Oncol 23 (2004)
127. Verweij J., van Oosterom A., Blay J.Y., et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 39 (2003) 2006-2011
128. Van Glabbeke M., Verweij J., Casali P., et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors (GIST) are predicted by different prognostic factors. An EORTC-ISG-AGITG study. J Clin Oncol 23 (2005) 5795-5804
129. Dileo P., Desai J., and Demetri G. Identification and clinical management of patients with gastrointestinal stromal tumors in the era of imatinib mesylate: incorporating the newest information into practice. J National Compr Cancer Netw 2 Suppl 1 (2004)
130. Dileo P., Randhawa R., Vansonnenberg E., et al. Safety and efficacy of percutaneous radio-frequency ablation (RFA) in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) with clonal evolution of lesions refractory to imatinib mesylate (IM). Proc Am Soc Clin Oncol (2004) 9024
131. Desai J., Shankar S., Skubitz K.M., et al. Clonal evolution of resistance to imatinib (IM) in patients (pts) with gastrointestinal stromal tumor (GIST): molecular and radiologic evaluation of new lesions. Proc Am Soc Clin Oncol (2004) 3010
132. Van den Abbeele A., Badawi R.D., Manola J., et al. Effects of cessation of imatinib mesylate (IM) therapy in patients (pts) with IM-refractory gastrointestinal stromal tumors (GIST) as visualized by FDG-PET scanning. Proc Am Soc Clin Oncol (2004) 3012
133. Demetri G., Desai J., Fletcher J.A., et al. SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). Proc Am Soc Clin Oncol 22 (2004) 3001
134. Demetri G.D., van Oosterom A.T., Blackstein M., et al. Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST [abstract]. Proc Am Soc Clin Oncol 24 (2005)
135. Bauer S., Yu L., Read M., Normant E., Demetri G.D., and Fletcher J.A. IPI504, a novel HSP90 inhibitor causes inhibition and degradation of KIT in imatinib-resistant GIST: rationale for therapeutic targeting in GIST (2005), AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics, Philadelphia C49
136. Bauer S., Yu L., Demetri G.D., and Fletcher J.A. Targeting HSP90 in IM-resistant GIST: KIT degradation as a broadly relevant salvage strategy. Proceedings of the 11th Annual Meeting, Connective Tissue Oncology Society. Boca Raton (2005) a457
137. Dematteo R.P., Heinrich M.C., El Rifai W.M., and Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 33 (2002) 466-477
138. Hohenberger P., Schneider U., Rötzschke O., Kettelhack C., Pink D., and Reichardt P. Resection of progressive or residual tumor following treatment with imatinib for advanced GI stromal tumors. Ann Surg Oncol 11 (2004) s53